



May 15, 2025

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051.

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

Scrip Code: STAR

Scrip Code: 532531

Dear Madam/ Sir,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

Ref: De-merger of Identified Business of Arco Lab Private Limited (“Arco Lab”), a wholly owned subsidiary of the Company

In continuation to our intimation dated March 19, 2025, we wish to inform you that Board of Directors of Arco Lab Private Limited (“Arco Lab”) and Pivot Path Private Limited (currently a wholly owned subsidiary of Arco Lab hereinafter referred to as “Pivot Path”), at their meeting held today (i.e., May 15, 2025) have approved the Scheme of Arrangement for demerger of Life Sciences and Digital Innovation Capabilities (“Identified Business”) of Arco Lab into Pivot Path, pursuant to Section 230-232 of the Companies Act, 2013 and other applicable provisions of the Act and Rules framed thereunder.

Scheme is subject to necessary approvals including from the Shareholders and Creditors of participating entities and the Hon’ble National Company Law Tribunal (NCLT).

Requisite disclosures in terms of Regulation 30 of SEBI Listing Regulations read with applicable SEBI Circular dated November 11, 2024, is enclosed as an Annexure.

This is for your kind information and record purpose.

Thanks & regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No. A30515

Encl.: As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

Tel: +91-80-6784 0000 **Fax:** +91 80 6784 0700

Regd Off: ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

Tel:+91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com

Annexure

Disclosure pursuant to Regulation 30 of SEBI Listing Regulation read with SEBI Circular SEBI/HO/ CFD/PoD2/ CIR/ P/ 0155 dated November 11, 2024

**Scheme of Arrangement for Demerger involving
Arco Lab Private Limited (“Arco Lab”) and Pivot Path Private Limited (“Pivot Path”)**

#	Particulars
1.	Brief details of the division(s) to be demerged
	Life Sciences business and Digital Innovations business of Arco Lab is the Identified Business which shall be demerged into Pivot path. In terms of the Scheme of Arrangement, Demerged Undertaking shall include all the business, undertakings, activities, operation and properties, of whatsoever nature and kind and wherever situated, forming part of the Identified Business of Arco Lab, as a going concern. Appointed Date for the said demerger shall be April 10, 2025.
2.	Turnover of the demerged division and as percentage to the total turnover of the listed entity in the immediately preceding financial year/ based on financials of the last financial year
	Not Applicable as the demerger does not involve the Listed Entity.
3.	Rationale for demerger
	Arco Lab believes that the demerger of Identified Business is a strategic fit for serving the existing market and catering to additional volume in the pharmaceutical sector.
4	Brief details of change in shareholding pattern (if any) of all entities.
	Arco Lab is a wholly owned subsidiary of Strides (“Listed Entity”). Pursuant to demerger there shall be no change in shareholding of Arco Lab. Pivot Path is a wholly owned subsidiary of Arco Lab. Pursuant to demerger, Arco Lab’s Investment in Pivot Path shall stand cancelled and Shareholders of Arco Lab (i.e., Strides) shall receive Equity Shares of Pivot Path as per the exchange ratio of 1:1 as a consideration for Demerger. Consequently, Pivot Path shall become a wholly owned subsidiary of Strides.

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

Tel: +91-80-6784 0000 **Fax:** +91 80 6784 0700

Regd Off: ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

Tel:+91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com

5.	In case of cash consideration – amount or otherwise share exchange ratio.
	There is no cash consideration payable under the Scheme. Consideration for demerger shall be discharged by way of issue of Equity Shares by Pivot Path as per the following share entitlement ratio: 1 (One) fully paid-up equity share of face value of INR 10 (Rupees Ten only) each of Pivot Path Private Limited (“Resulting Company”), for every 1 (One) fully paid-up equity share of face value of INR 10 (Rupees Ten only) each held in the Arco Lab Private Limited (“Demerged Company”)
6.	Whether listing would be sought for the resulting entity
	Resulting entity – i.e., Pivot Path Private Limited is not proposed to be listed with any Stock Exchange pursuant to the Scheme.

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

Tel: +91-80-6784 0000 **Fax:** +91 80 6784 0700

Regd Off: ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

Tel:+91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com